Advertisement
Canada markets close in 5 hours 48 minutes
  • S&P/TSX

    21,958.69
    +73.31 (+0.33%)
     
  • S&P 500

    5,104.71
    +56.29 (+1.11%)
     
  • DOW

    38,292.87
    +207.07 (+0.54%)
     
  • CAD/USD

    0.7320
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    83.98
    +0.41 (+0.49%)
     
  • Bitcoin CAD

    88,109.14
    +1,168.41 (+1.34%)
     
  • CMC Crypto 200

    1,338.43
    -58.11 (-4.16%)
     
  • GOLD FUTURES

    2,354.50
    +12.00 (+0.51%)
     
  • RUSSELL 2000

    1,998.52
    +17.41 (+0.88%)
     
  • 10-Yr Bond

    4.6490
    -0.0570 (-1.21%)
     
  • NASDAQ

    15,911.86
    +300.10 (+1.92%)
     
  • VOLATILITY

    15.26
    -0.11 (-0.72%)
     
  • FTSE

    8,129.68
    +50.82 (+0.63%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6835
    +0.0014 (+0.21%)
     

This Dividend Stock Just Made a Very Bullish Crossover

When dividend stocks are on the rise, it could be time to buy them up. That's because an increase in the share price will result in a declining yield. Plus, buying before it takes off could allow investors to benefit from the potential gains earned on a rising stock, which can complement the cash flow generated from its recurring dividend payments.

That's where healthcare stock Becton, Dickinson (NYSE:BDX) finds itself in today. Its yield of 1.3% is in line with the S&P 500 average and can be a good source of regular cash flow for investors. And of late, the stock has been picking up some momentum. Earlier this month, it made a bullish crossover with its 50-day moving average climbing higher than its 200 day average. When that happens, that has the potential to trigger more momentum buying.

It could also be a sign of more optimism behind the medical device company, which could see better results ahead if there's a return to normalcy in the healthcare industry – assuming, of course, that the omicron variant doesn't derail that.

Read:

The company is coming off an already strong quarter where for the period ending Sept. 30, 2021, its sales of $5.1 billion rose 7.3% year over year. And with expenses remaining fairly consistent, that allowed the company's bottom line to see a large 136% improvement in its earnings per share, which rose from $0.36 to $0.85. If it can build on those results, this could be an underrated dividend stock to own this year.